Immunological basis of specific immunotherapy in IgE-mediated allergic reactions;Grundlagen der spezifischen immuntherapie IgE-vermittelter allergischer reaktionen

Therapeutische Umschau

Volumn 58, Issue 5, 2001, Pages 274-277

  Akdis, C A ^b   Blaser, Kurt ^a  

^a Schweizerisches Inst F A   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN E;

ARTICLE; BLOOD; DESENSITIZATION; HUMAN; HYPERSENSITIVITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE;

CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; IMMUNOGLOBULIN E; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 0035346017     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.58.5.274     Document Type: Article

References (17)

1. Carballido JM, Carballido-Perrig N, Oberli-Schrämmli A, Blaser K. Regulation of IgE and IgG4 responses by allergen specific T cell clones to bee venom phospholipase A2 in vitro. J Allergy Clin Immunol 1994; 93: 758-67.
2. Carballido JM, Carballido-Perrig N, Terres G, Heusser CH, Blaser K. Bee venom phospholipase A2-specific T cell clones from human allergic and non-allergic individuals: Cytokine patterns change in response to the antigen concentration. Eur J Immunol 1992; 27: 515-21.
3. Carballido JM, Faith A, Carballido-Perrig, Blaser K. The intensity of T cell receptor engagement determines the cytokine pattern of human allergen-specific Th cells. Eur J Immunol 1997; 27: 515-21.
4. Carballido JM, Carballido-Perrig N, Kägi MK, et al. T cell epitope specificity in human allergic and non-allergic subjects to bee venom phospholipase A2. J Immunol 1993; 150: 3582-91.
5. Blaser K, Carballido JM, Faith A, Crameri, Akdis CA. Determinants and Mechanisms of Human Immune Responses to Bee Venom Phospholipase A2. Int Arch Allergy Immunol 1998; 117: 1-10.
6. Müller UR, Akdis AC, Fricker M, et al. Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in bee sting allergic patients. J Allergy Clin Immunol 1998; 101: 747-54.
7. Haselden BM, Kay AB, Larche M. Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol. 2000; 122: 229-37.
8. Akdis CA, Akdis M, Blesken T, et al. Epitope specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996; 98: 1676-83.
9. Faith A, Akdis CA, Akdis M, Simon HU, Blaser K. Defective TCR stimulation in anergized type 2 T helper cells correlates with abrogated p561ck and ZAP70 tyrosine kinase activities. J Immunol 1997; 159: 53-60.
10. Akdis CA, Blesken T, Akdis M, Wüthrich W, Blaser K. The role of IL-10 in specific immunotherapy. J Clin Invest 1998; 102: 98-106.
11. Bellinghousen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997; 27: 1131-9.
12. Akdis CA, Blaser K. IL-10 induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999; 13: 603-9.
13. Akdis CA, Joss A, Akdis M, Faith A, Blaser K. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 2000; 14: 1666-8.
14. Akdis CA, Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy 2000; 55: 522-30.
15. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102: 157-64.
16. Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K. Differential regulation of human T-cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998; 28: 914-25.
17. Fuchs T, Fuchs E. Die subkutane allergenspezifische Immuntherapie (Hyposensibilisierung). In: Fuchs E, Schulz KH, Eds. Manuale allergologikum Vll.3.2. Dustry Verlag Dr. Karl Feistle, Deisenhofen (D).